CO2018011733A2 - Composición farmacéutica - Google Patents
Composición farmacéuticaInfo
- Publication number
- CO2018011733A2 CO2018011733A2 CONC2018/0011733A CO2018011733A CO2018011733A2 CO 2018011733 A2 CO2018011733 A2 CO 2018011733A2 CO 2018011733 A CO2018011733 A CO 2018011733A CO 2018011733 A2 CO2018011733 A2 CO 2018011733A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical compositions
- freeze
- antibody
- pharmaceutical composition
- drying
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608323.0A GB201608323D0 (en) | 2016-05-12 | 2016-05-12 | Pharmaceutical compositions |
| PCT/EP2017/061261 WO2017194646A1 (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018011733A2 true CO2018011733A2 (es) | 2019-02-08 |
Family
ID=56320265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0011733A CO2018011733A2 (es) | 2016-05-12 | 2018-10-30 | Composición farmacéutica |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11407835B2 (https=) |
| EP (1) | EP3454899B1 (https=) |
| JP (1) | JP7126454B2 (https=) |
| KR (1) | KR102436694B1 (https=) |
| CN (1) | CN109069643A (https=) |
| AR (1) | AR108449A1 (https=) |
| AU (1) | AU2017264553A1 (https=) |
| BR (1) | BR112018072264A2 (https=) |
| CA (1) | CA3022124A1 (https=) |
| CL (1) | CL2018003178A1 (https=) |
| CO (1) | CO2018011733A2 (https=) |
| EA (1) | EA201892446A1 (https=) |
| ES (1) | ES2977545T3 (https=) |
| GB (1) | GB201608323D0 (https=) |
| IL (1) | IL262654A (https=) |
| MX (1) | MX2018013215A (https=) |
| SG (1) | SG11201809229VA (https=) |
| WO (1) | WO2017194646A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122020023215B1 (pt) | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| WO2019180261A1 (en) * | 2018-03-23 | 2019-09-26 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| MX2022011248A (es) * | 2020-03-11 | 2022-12-15 | Selecta Biosciences Inc | Metodos y composiciones relacionados con nanoportadores sinteticos. |
| US20240287191A1 (en) * | 2020-06-29 | 2024-08-29 | Hanall Biopharma Co., Ltd. | Formulation for anti-fcrn antibody |
| JP2024518536A (ja) * | 2021-05-12 | 2024-05-01 | アナプティスバイオ インコーポレイティッド | 抗体組成物 |
| PE20241936A1 (es) | 2021-12-01 | 2024-09-24 | UCB Biopharma SRL | Formulaciones que comprenden fab-peg |
| WO2023224112A1 (ja) * | 2022-05-20 | 2023-11-23 | 株式会社ダイセル | 液状医薬組成物 |
| AU2023281650A1 (en) | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| CN115708810A (zh) * | 2022-11-03 | 2023-02-24 | 浙江新码生物医药有限公司 | 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途 |
| EP4676963A1 (en) * | 2023-03-08 | 2026-01-14 | Immunovant Sciences GmbH | High concentration protein formulations with polysorbate excipients and methods of making the same |
| CN121889167A (zh) * | 2023-09-13 | 2026-04-17 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| MX2008014391A (es) * | 2006-05-12 | 2009-03-06 | Bharat Biotech Int Ltd | Una composicion util como vacuna. |
| AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| JP2012530721A (ja) * | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | 小モジュール免疫薬のための凍結乾燥製剤 |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| US8788028B2 (en) | 2010-07-28 | 2014-07-22 | Medtronic, Inc. | Parasympathetic stimulation to enhance tachyarrhythmia detection |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US9592289B2 (en) * | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| EP4527855A3 (en) * | 2012-03-26 | 2025-06-11 | Sanofi | Stable igg4 based binding agent formulations |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| WO2014093206A1 (en) | 2012-12-13 | 2014-06-19 | Merck Sharp & Dohme Corp. | Lyophilized spherical pellets of anti-il-23 antibodies |
| US20150225479A1 (en) * | 2014-02-12 | 2015-08-13 | Sanofi | Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations |
| CN107073113A (zh) | 2014-10-18 | 2017-08-18 | 辉瑞大药厂 | 抗il‑7r抗体组合物 |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
-
2016
- 2016-05-12 GB GBGB1608323.0A patent/GB201608323D0/en not_active Ceased
-
2017
- 2017-05-11 EP EP17725544.5A patent/EP3454899B1/en active Active
- 2017-05-11 ES ES17725544T patent/ES2977545T3/es active Active
- 2017-05-11 JP JP2018559221A patent/JP7126454B2/ja active Active
- 2017-05-11 EA EA201892446A patent/EA201892446A1/ru unknown
- 2017-05-11 WO PCT/EP2017/061261 patent/WO2017194646A1/en not_active Ceased
- 2017-05-11 AR ARP170101248A patent/AR108449A1/es not_active Application Discontinuation
- 2017-05-11 BR BR112018072264-2A patent/BR112018072264A2/pt not_active IP Right Cessation
- 2017-05-11 KR KR1020187036132A patent/KR102436694B1/ko active Active
- 2017-05-11 MX MX2018013215A patent/MX2018013215A/es unknown
- 2017-05-11 CA CA3022124A patent/CA3022124A1/en active Pending
- 2017-05-11 AU AU2017264553A patent/AU2017264553A1/en not_active Abandoned
- 2017-05-11 CN CN201780028404.3A patent/CN109069643A/zh active Pending
- 2017-05-11 US US16/300,522 patent/US11407835B2/en active Active
- 2017-05-11 SG SG11201809229VA patent/SG11201809229VA/en unknown
-
2018
- 2018-10-28 IL IL262654A patent/IL262654A/en unknown
- 2018-10-30 CO CONC2018/0011733A patent/CO2018011733A2/es unknown
- 2018-11-08 CL CL2018003178A patent/CL2018003178A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200048346A1 (en) | 2020-02-13 |
| GB201608323D0 (en) | 2016-06-29 |
| CA3022124A1 (en) | 2017-11-16 |
| KR20190008320A (ko) | 2019-01-23 |
| BR112018072264A2 (pt) | 2019-02-12 |
| EA201892446A1 (ru) | 2019-04-30 |
| CN109069643A (zh) | 2018-12-21 |
| ES2977545T3 (es) | 2024-08-26 |
| EP3454899A1 (en) | 2019-03-20 |
| AU2017264553A1 (en) | 2018-12-13 |
| KR102436694B1 (ko) | 2022-08-25 |
| US11407835B2 (en) | 2022-08-09 |
| WO2017194646A1 (en) | 2017-11-16 |
| EP3454899C0 (en) | 2024-03-20 |
| IL262654A (en) | 2018-12-31 |
| EP3454899B1 (en) | 2024-03-20 |
| MX2018013215A (es) | 2019-02-21 |
| RU2018141591A3 (https=) | 2021-01-13 |
| JP7126454B2 (ja) | 2022-08-26 |
| AR108449A1 (es) | 2018-08-22 |
| RU2018141591A (ru) | 2020-06-15 |
| CL2018003178A1 (es) | 2019-02-01 |
| JP2019514998A (ja) | 2019-06-06 |
| SG11201809229VA (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018011733A2 (es) | Composición farmacéutica | |
| BR112019009113A2 (pt) | formulações de vírus adenoassociado | |
| ECSP23041058A (es) | Formulación subcutánea de anticuerpo anti-her2 | |
| BRPI0915696B8 (pt) | composição de vacina de rotavírus liofilizada e método de preparar a referida composição | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| WO2016184576A3 (en) | Dry powder composition comprising long-chain rna | |
| MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
| DOP2019000250A (es) | Composicion farmaceutica que comprende selexipag | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| CR20200410A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027). | |
| BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
| BR112012012460A2 (pt) | "método de liofilização, composições e kits". | |
| MX2018005063A (es) | Polipéptidos condicionalmente activos. | |
| BR112019006907A2 (pt) | proteína liofilizada estável em temperatura ambiente | |
| JP2019514998A5 (https=) | ||
| EA202090967A1 (ru) | Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус, и процесс их приготовления | |
| AR103544A1 (es) | FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a | |
| RU2016105462A (ru) | Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| EP4606820A3 (en) | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents | |
| CY1125375T1 (el) | Ενα λυοφιλοποιημενο φαρμακευτικο σκευασμα και η χρηση του | |
| BR112018014277A2 (pt) | formulação, e, método de preparação de uma solução injetável de um axl-adc | |
| CO2019003876A2 (es) | Formulación farmacéutica parenteral que contiene ácido carglúmico | |
| AR115713A1 (es) | FORMULACIÓN ESTABLE DE ALTA CONCENTRACIÓN PARA ANTICUERPOS ANTI-FXIa |